Why international multi-database studies
Not simply pooling data from many countries — but answering one question consistently across very different settings.
Definition
What is an international multi-database study?
It is not the simple merging of data from several countries. It is answering the same disease or treatment question — with a consistent research question, a shared analytic logic and a transparent method — across different healthcare systems, data structures and population backgrounds.
Why does that matter? Because populations and settings are diverse: data from a single country may not represent other populations, healthcare systems or clinical practices. A finding that holds in one setting still has to prove itself elsewhere.
This page explains why multinational research matters. The Methods & Technology page explains how IMPRESIVE makes it consistent and reproducible.
The value
Why cross-national collaboration matters
Power & precision
Increase event counts and statistical precision — for rare diseases, rare adverse events, specific subgroups and recently introduced medications a single country cannot accumulate alone.
Compare across systems
Contrast treatment patterns, disease burden, healthcare utilization and outcomes across countries.
Test transportability
Assess whether findings transfer and remain valid across settings.
Support decisions
Inform regulatory, HTA, clinical and policy decisions with multi-country evidence.
Privacy-preserving
Collaborate internationally without transferring raw personal data.
Rapid response
Countries that adopted a medication earlier help identify potential safety signals sooner — for everyone.
Why Asia needs its own infrastructure
Western findings cannot simply be assumed to apply
Asian countries differ substantially from one another — and from Europe and the United States — in population composition, healthcare systems, clinical practice, access to medicines and how data are generated. Establishing Asia's own multinational research infrastructure makes it possible to assess whether findings hold across countries, and to identify heterogeneity that requires locally informed interpretation.
Reading the differences
Consistency and heterogeneity
When countries produce different results, that is not necessarily an error.
Divergent findings may reflect genuine differences in data, populations, healthcare systems or implementation — and understanding why results differ is itself evidence. A multi-database study is designed to distinguish real heterogeneity from methodological noise, rather than hide it behind a single pooled number.
Fit-for-purpose
When is a cross-national study the right choice?
✔ Well suited when…
- Event counts in a single country are insufficient
- Multi-country comparison is needed
- Extrapolation and transportability must be assessed
- Post-marketing safety surveillance is required
- Studying new drugs, rare diseases or special populations
- Rapid multi-country RWE is needed to support a decision
- Comparing disease burden or outcomes across treatment models or health systems
✘ Often not suited when…
- The question is purely a single-country policy matter
- Variable definitions are not yet clear
- Data quality differs too greatly between countries
- Exposure, outcome or time-zero cannot be defined consistently
- Local analytic and governance capacity is lacking
"Not yet suited" rarely means never — it usually means feasibility work first: clarifying definitions, profiling the data, and building readiness before the study runs.
Have a question that needs more than one country to answer?
IMPRESIVE helps turn it into a feasible, decision-ready study.
Submit a research topic